AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, which spun out of Pfizer ...

Cerevel Therapeutics’ Parkinson’s ... reinforcing its blockbuster potential and no doubt delighting AbbVie, which has agreed to buy the company in an $8.7 billion deal. Tavapadon is just ...

Rosen Law Firm, a global investor rights law firm, reminds persons or entities that (1) sold or otherwise disposed of the ...

2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc. (c) sold shares of Cerevel stock contemporaneously with Bain Capital's purchase of shares on or about October 16 ...

2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc.; and/or (3) sold shares of Cerevel stock contemporaneously with Bain Capital's purchase of shares on or about ...

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including ...

Just 51 days after the offering, Cerevel publicly announced that AbbVie agreed to acquire Cerevel for $45 per share – i.e., nearly double the offering price – and Bain's discounted purchases ...

Calling AbbVie Inc. (NYSE:ABBV) one of his “absolute favorites” during the recent episode of Mad Money, Cramer said: “Or how about one of my absolute favorites right here too, AbbVie.

Evaluate AbbVie Inc. vs. Pfizer Inc. amidst tariff disputes and drug pricing policies. Click for our comparison of ABBV and ...

AbbVie has recently announced a significant collaboration with ADARx Pharmaceuticals, aiming to develop innovative siRNA therapeutics, and received accelerated FDA approval for EMRELIS, a ...